Ceftazidime-avibactam as salvage therapy for infections caused by Enterobacteriales coresistant to carbapenems and polymyxins

33Citations
Citations of this article
68Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this article, we report a case series of patients with infections caused by Enterobacteriales coresistant to carbapenems and polymyxins who were treated with ceftazidime/avibactam (CAZ-AVI) salvage therapy on a compassionate-use protocol. We enrolled 29 adult patients in 3 centers that had an infection due to a resistant microorganism and for whom the treatments available were considered ineffective, treated them with CAZ-AVI, and assessed clinical and microbiological cure at the end of treatment and all-cause mortality at 14 days and 30 days. The antimicrobial susceptibility profile was determined using broth microdilution, and total genomic DNA was sequenced. Twelve (41.4%) patients had bacteremia, and 48.3% (14/29) of the infections were treated with combination therapy. All strains were producers of KPC-2 and were susceptible to CAZ-AVI (MIC90, 1 µg/ml). Clinical success was high (24/29 [82.7%; 95% confidence interval, 64.2 to 94.2%]), even for the bacteremic cases (75%). The 14-day and 30-day mortality rates were 9/29 (31%) and 15/29 (51.7%), respectively. The 14-day mortality rate for pneumonia was the same as that for bloodstream infections (33.3%) and although not significant, we found that patients with renal impairment that received adjusted doses of CAZ-AVI had high mortality (4/9 [44%]; P = 0.22). We concluded that CAZ-AVI is an option for the treatment of severe infections due to difficult-to-treat drug-resistant Enterobacteriales.

Cite

CITATION STYLE

APA

Guimarães, T., Nouér, S. A., Martins, R. C. R., Perdigão Neto, L. V., Martins, W. M. B. S., Barbosa, A. C. N., … Gales, A. C. (2019). Ceftazidime-avibactam as salvage therapy for infections caused by Enterobacteriales coresistant to carbapenems and polymyxins. Antimicrobial Agents and Chemotherapy, 63(10). https://doi.org/10.1128/AAC.00528-19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free